TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 1969-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.ttuhsc.edu
Clinical Trials
93
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (73 trials with phase data)• Click on a phase to view related trials
L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD
- Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)Autism Spectrum Disorder (ASD)
- First Posted Date
- 2025-09-24
- Last Posted Date
- 2025-09-24
- Lead Sponsor
- Texas Tech University Health Sciences Center
- Target Recruit Count
- 24
- Registration Number
- NCT07189442
- Locations
- 🇺🇸
Texas Tech University, Lubbock, Texas, United States
Effects of Exposure to a Single-electrode Electroencephalography-guided Binaural Beat Audio Track on Sustained Attention and Subjective Well-being Among Healthy Adults
- Conditions
- Psychomotor SpeedInhibitory ControlSustained AttentionMemory EncodingWell-being
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Texas Tech University Health Sciences Center
- Target Recruit Count
- 25
- Registration Number
- NCT07165899
- Locations
- 🇺🇸
Texas Tech University Health Sciences Center, Lubbock, TX, USA, Lubbock, Texas, United States
Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
- Conditions
- Orthopedic Trauma Surgery PatientsPostoperative PainOpioid UsePost-traumatic Stress Disorder (PTSD)Depression
- Interventions
- Drug: standard general anesthesia
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Texas Tech University Health Sciences Center
- Target Recruit Count
- 90
- Registration Number
- NCT06903819
- Locations
- 🇺🇸
Texas Tech University Health Sciences Center Lubbock, Lubbock, Texas, United States
🇺🇸University Medical Center, Lubbock, Texas, United States
Early Childhood Obesity Among Rural Residents of West Texas
- Conditions
- Obesity
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Texas Tech University Health Sciences Center
- Target Recruit Count
- 480
- Registration Number
- NCT06831097
- Locations
- 🇺🇸
Texas Tech University Health Sciences Center, Lubbock, Texas, United States
Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Texas Tech University Health Sciences Center
- Target Recruit Count
- 130
- Registration Number
- NCT06349772
- Locations
- 🇺🇸
Texas Tech University Health Sciences Center, Lubbock, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
Study Reveals Significant Pregnancy Risks for Minority Women with Cancer
New research from Texas Tech University Health Sciences Center shows racial and ethnic minority women with cancer face up to 40% higher risk of adverse pregnancy outcomes compared to their white counterparts.
Breakthrough Medications Show Promise in Reducing Lipoprotein(a) Levels by Up to 90%
Two novel therapies - oral muvalaplin and injectable zerlasiran - demonstrate remarkable efficacy in lowering lipoprotein(a) levels by 80-90% with minimal side effects in clinical trials.
Optimizing Kidney Cancer Treatment: Keytruda, Inlyta, and Novel Approaches for Non-Clear Cell RCC
• Considerations for discontinuing Keytruda (pembrolizumab) and Inlyta (axitinib) after two years involve balancing recurrence risk and side effects, necessitating individualized patient-physician discussions. • For non-clear cell chromophobe renal cell carcinoma, IO-TKI combinations like Lenvima (lenvatinib) plus Keytruda or Cabometyx (cabozantinib) plus Opdivo (nivolumab) show promise, with treatment choice depending on approval status. • Managing fatigue and chronic kidney disease in RCC patients requires investigating reversible causes and employing supportive measures, with nephrologist involvement for significant renal impairment.